# US 9,969,985 B2 · Modified human rotaviruses and uses therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,969,985 B2
- Document ID: US9969985B2
- Status: Granted
- Kind: B2
- Application number: 14/423,660
- Filed: 2013-08-26
- Published: 2015-11-26
- Granted: 2018-05-15
- Earliest claimed: 2012-08-27
- Assignees: Murdoch Childrens Research Institute
- Applicants: Murdoch Childrens Research Institute
- Inventors: Carl Kirkwood; Ruth Frances Bishop; Graeme Laurence Barnes
- Web page: https://patentgrep.com/patent/US9969985B2

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 39/15: Reoviridae, e.g. calf diarrhea virus
- A61P 31/14: for RNA viruses
- C07K 14/005: from viruses
- C12Q 1/701: {Specific hybridization probes}
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/5254: {avirulent or attenuated}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- C12N 2720/12321: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2720/12322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2720/12334: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2720/12363: by chemical treatment
- C12N 2720/12364: by serial passage
- C12Q 2600/156: Polymorphic or mutational markers
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present disclosure relates generally to the field of viral vaccines. Particularly, the present disclosure provides a modified Vero-adapted human rotavirus strain and a culturing method to produce high titer virus, a rotavirus vaccine, vaccination protocols and diagnostic and prognostic assays.

## Claims

### Claim 1

An isolated Vero-adapted rotavirus RV3 strain comprising at least one of a NSP2 nucleotide sequence comprising SEQ ID NO: 33, a NSP4 nucleotide sequence comprising SEQ ID NO: 37, a NSP5/6 nucleotide sequence comprising SEQ ID NO: 29, a VP1 nucleotide sequence comprising SEQ ID NO: 49, a VP3 nucleotide sequence comprising SEQ ID NO: 57, a VP4 nucleotide sequence comprising SEQ ID NO: 61, a NSP4 amino acid sequence comprising SEQ ID NO: 38, a NSP5 amino acid sequence comprising SEQ ID NO: 30, a VP1 amino acid sequence comprising SEQ ID NO: 50, a VP3 amino acid sequence comprising SEQ ID NO: 58, or a VP4 amino acid sequence comprising SEQ ID NO: 62.

### Claim 2 (depends on 1)

The isolated Vero-adapted rotavirus RV3 strain of claim 1, comprising a NSP2 nucleotide sequence comprising SEQ ID NO: 33, a NSP4 nucleotide sequence comprising SEQ ID NO: 37, a NSP5/6 nucleotide sequence comprising SEQ ID NO: 29, a VP1 nucleotide sequence comprising SEQ ID NO: 49, a VP3 nucleotide sequence comprising SEQ ID NO: 57 and a VP4 nucleotide sequence comprising SEQ ID NO: 61; or comprising a NSP4 amino acid sequence comprising SEQ ID NO: 38, a NSP5 amino acid sequence comprising SEQ ID NO: 30, a VP1 amino acid sequence comprising SEQ ID NO: 50, a VP3 amino acid sequence comprising SEQ ID NO: 58 and a VP4 amino acid sequence comprising SEQ ID NO: 62.

### Claim 3 (depends on 1)

An attenuated live or killed rotavirus (RV) composition comprising the isolated Vero-adapted rotavirus RV3 of claim 1 and one or more pharmaceutically acceptable carriers, diluents and/or excipients.

### Claim 4 (depends on 2)

An attenuated live or killed rotavirus (RV) composition comprising the isolated Vero-adapted rotavirus RV3 of claim 2 and one or more pharmaceutically acceptable carriers, diluents and/or excipients.